---
qid: ing_8ed1566b1a__aws__local
question: 'Explain: Pioneering the Science of AI Evaluation in Healthcare'
topic: AI
model: openai/gpt-oss-20b
provider: lmstudio
input_tokens: 231
output_tokens: 387
total_tokens: 618
web_searches: 0
cost_usd: 0.0
generated_at: '2026-09-07T10:49:01-05:00'
sources: []
---

**Situation & Task**  
In 2023 I led a cross‑functional team at a hospital network to build the first end‑to‑end AI evaluation framework for radiology diagnostics. The goal was to quantify model performance, bias, and clinical impact before deployment.

**Action**  
- **Ownership + Dive Deep:** I defined key metrics (AUC, F1, false‑positive rate by race/ethnicity) and built a data lake in **Amazon S3** with **Glue** cataloging.  
- Used **AWS SageMaker Ground Truth** to annotate a 200k‑case validation set, then trained comparison models on **SageMaker Pipelines**.  
- Implemented continuous monitoring with **Amazon CloudWatch** alarms and a **Lambda**‑driven alert pipeline that auto‑re‑runs evaluation when drift >5%.  
- Presented findings in a live dashboard built on **QuickSight**, integrating cost estimates from **AWS Cost Explorer** to show ROI.

**Result**  
The framework reduced false positives by 18 % (from 12.4 % to 10.2 %) and identified a 3‑point bias gap that we corrected, improving equity scores. Deployment time dropped from 6 months to 2 months, saving ~$1.2M in projected diagnostic costs over two years.

**Learnings & Bar‑Raiser Insight**  
I learned that quantifying bias early prevents costly post‑market fixes. A bar‑raiser would note my ownership of the end‑to‑end pipeline, deep dive into data quality, and clear, metric‑driven impact—exactly what Amazon looks for in high‑stakes AI initiatives.

_Written by openai/gpt-oss-20b running locally. Machine-generated, not reviewed._
